Interleukin-21 in cancer immunotherapy: Friend or foe?

Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21...

Descripción completa

Detalles Bibliográficos
Autores principales: Stolfi, Carmine, Pallone, Francesco, MacDonald, Thomas T., Monteleone, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Point of View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382872/
https://www.ncbi.nlm.nih.gov/pubmed/22737612
http://dx.doi.org/10.4161/onci.19122
_version_ 1782236564353449984
author Stolfi, Carmine
Pallone, Francesco
MacDonald, Thomas T.
Monteleone, Giovanni
author_facet Stolfi, Carmine
Pallone, Francesco
MacDonald, Thomas T.
Monteleone, Giovanni
author_sort Stolfi, Carmine
collection PubMed
description Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit.
format Online
Article
Text
id pubmed-3382872
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33828722012-06-26 Interleukin-21 in cancer immunotherapy: Friend or foe? Stolfi, Carmine Pallone, Francesco MacDonald, Thomas T. Monteleone, Giovanni Oncoimmunology Point of View Interleukin (IL)-21, a cytokine produced by activated conventional CD4+ T lymphocytes and Natural Killer T cells, drives anti-tumor immunity in the skin and kidney. However IL-21 is also pro-inflammatory in many tissues and promotes colitis-associated colon cancer. Understanding the biology of IL-21 in these different situations is needed to ensure maximal therapeutic benefit. Landes Bioscience 2012-05-01 /pmc/articles/PMC3382872/ /pubmed/22737612 http://dx.doi.org/10.4161/onci.19122 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Point of View
Stolfi, Carmine
Pallone, Francesco
MacDonald, Thomas T.
Monteleone, Giovanni
Interleukin-21 in cancer immunotherapy: Friend or foe?
title Interleukin-21 in cancer immunotherapy: Friend or foe?
title_full Interleukin-21 in cancer immunotherapy: Friend or foe?
title_fullStr Interleukin-21 in cancer immunotherapy: Friend or foe?
title_full_unstemmed Interleukin-21 in cancer immunotherapy: Friend or foe?
title_short Interleukin-21 in cancer immunotherapy: Friend or foe?
title_sort interleukin-21 in cancer immunotherapy: friend or foe?
topic Point of View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382872/
https://www.ncbi.nlm.nih.gov/pubmed/22737612
http://dx.doi.org/10.4161/onci.19122
work_keys_str_mv AT stolficarmine interleukin21incancerimmunotherapyfriendorfoe
AT pallonefrancesco interleukin21incancerimmunotherapyfriendorfoe
AT macdonaldthomast interleukin21incancerimmunotherapyfriendorfoe
AT monteleonegiovanni interleukin21incancerimmunotherapyfriendorfoe

Ejemplares similares